Daniel Shelly

Company: PolTREG Immuthera

Job title: Chief Business Development Officer

Bio:

Daniel Shelly is a member of the Executive Leadership Team at PolTREG, where he leads efforts to advance next-generation T-regulatory cell therapies for autoimmune diseases. He previously served as VP of Business Development at Prescient Therapeutics, driving CAR-immune cell therapy and targeted therapy programs. With over 19 years of experience in biopharma business development and alliances, he has also held leadership roles at PATH and co-led its COVID-19 task force. He is an adjunct professor in the Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.

Seminars:

Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies 1:40 pm

Expand therapeutic approaches beyond B-cell depletion Highlight safety challenges with depletion in comparison to tolerance with Tregs Explore the long-term biological effects of B-cell depletion and immune reprogramming therapiesRead more

day: Conference Day One Pink Track P2

Driving Innovation Through Treg Data & Antigen Targeting to Unlock Treg Therapeutic Potential 3:15 pm

Utilize polyclonal Treg data to guide therapeutic direction and inform next-generation cell therapy design Highlight PolTREG and Immuthera’s latest Type 1 Diabetes findings to demonstrate clinical progress and therapeutic potential Advance disease-specific Treg therapies by leveraging antigen-driven precision for durable immune modulationRead more

day: Conference Day Two P2